Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 1/20 | 1.00 |
| ▸ | MAX | P61244 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.68 |
| ▸ | MAPT | P10636 | 7/20 | 0.68 |
| ▸ | GAA | P10253 | 3/20 | 0.68 |
| ▸ | HPGD | P15428 | 5/20 | 0.68 |
| ▸ | CASP1 | P29466 | 3/20 | 0.68 |
| ▸ | CASP7 | P55210 | 3/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.68 |
| ▸ | POLB | P06746 | 3/20 | 0.63 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | USP2 | O75604 | 1/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | ESR1 | P03372 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1718423 | 0.89 | MYC (0.81) | MYCMAXKDM4EALDH1A1MAPT | |
| SCHEMBL1718904 | 0.86 | MYC (0.75) | MYCMAXKDM4EALDH1A1MAPT | |
| SCHEMBL30612821 | 0.85 | ALDH1A1 (0.79) | MYCMAXKDM4EALDH1A1MAPT | |
| SCHEMBL1718635 | 0.84 | ALDH1A1 (0.75) | MYCMAXKDM4EALDH1A1MAPT | |
| SCHEMBL1718428 | 0.84 | MYC (0.72) | MYCMAXKDM4EALDH1A1MAPT | |
| SCHEMBL1718140 | 0.83 | KDM4E (0.77) | MYCMAXKDM4EALDH1A1MAPT | |
| SCHEMBL1718655 | 0.83 | ALDH1A1 (0.71) | MYCMAXKDM4EALDH1A1MAPT | |
| SCHEMBL14014121 | 0.82 | KDM4E (0.78) | MYCMAXKDM4EALDH1A1MAPT | |
| SCHEMBL1718669 | 0.82 | KDM4E (0.75) | MYCMAXKDM4EALDH1A1MAPT | |
| SCHEMBL1718546 | 0.82 | MAPT (0.72) | MYCMAXKDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190085404-A1 | METHODS OF IDENTIFYING AND TREATING IMMUNE CHECKPOINT INHIBITOR-RESPONSIVE NEOPLASMS AND CELLS, TRANSGENIC ANIMALS AND KITS FOR USE THEREIN | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2019-03-21 | — | — | US | disclosed |
| US-20160237490-A1 | SUPER-ENHANCERS AND METHODS OF USE THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH | 2016-08-18 | — | — | US | disclosed |
| US-20160237490-A1 | SUPER-ENHANCERS AND METHODS OF USE THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH | 2016-08-18 | — | — | US | disclosed |
| US-9181580-B2 | Super-enhancers and methods of use thereof | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2015-11-10 | — | — | US | disclosed |
| US-9181580-B2 | Super-enhancers and methods of use thereof | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2015-11-10 | — | — | US | disclosed |
| US-9155724-B2 | Combination methods for treatment of disease | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2015-10-13 | — | — | US | disclosed |
| US-9155724-B2 | Combination methods for treatment of disease | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2015-10-13 | — | — | US | disclosed |
| US-20150111761-A1 | SUPER-ENHANCERS AND METHODS OF USE THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH | 2015-04-23 | — | — | US | disclosed |
| US-20150111761-A1 | SUPER-ENHANCERS AND METHODS OF USE THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH | 2015-04-23 | — | — | US | disclosed |
| US-20140296218-A1 | SUPER-ENHANCERS AND METHODS OF USE THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2014-10-02 | — | — | US | disclosed |
| US-20140296218-A1 | SUPER-ENHANCERS AND METHODS OF USE THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2014-10-02 | — | — | US | disclosed |
| US-20130053415-A1 | COMBINATION METHODS FOR TREATMENT OF DISEASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-02-28 | — | — | US | disclosed |
| US-20130053415-A1 | COMBINATION METHODS FOR TREATMENT OF DISEASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053415-A1 | COMBINATION METHODS FOR TREATMENT OF DISEASE | NFATC1, IRF3, BCOR | MYC 81/4885MAX 4342/4885KDM4E 2087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.